Mediators of the benefit of sotagliflozin in patients with worsening heart failure in SOLOIST-WHF

25 August 2023 (07:30 - 18:30)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Professor Bertram Pitt

University of Michigan, Ann Arbor (United States of America)

5 More presentations in this session

Presentation thumbnail

Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial

Doctor S. Chatur (Boston, US)

Abstract Slides Video

Presentation thumbnail

Echocardiographic characterization of patients with supranormal ejection fraction: pooled core laboratory analysis of the TOPCAT and PARAGON-HF trials

Doctor X. Wang (Boston, US)

Abstract Slides Video

Presentation thumbnail

Dietary sodium intake and outcomes: a secondary analysis from SODIUM - HF

Professor C. Saldarriaga (Medellin, CO)

Abstract Slides Video

Presentation thumbnail

Influence of background therapy on efficacy of dapagliflozin in patients with heart failure and improved ejection fraction

Doctor M. Pabon (Boston, US)

Abstract Slides Video

Presentation thumbnail

Effects of empaglifozin on collagen biomarkers in patients with heart failure. Results from the EMPEROR trials

Doctor M. Sumin (Mainz, DE)

Abstract Slides Video

Access the full session

Session thumbnail

Insights from recent HFpEF trials 1

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023

You may be interested in

Congress Presentation

Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion

Congress Presentation

The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources